For relapsed or refractory T-cell lymphoma, several FDA-approved drugs are available. Here’s a list of some key treatments:

1. Brentuximab vedotin (Adcetris): This is an antibody-drug conjugate that targets CD30, which is expressed in some T-cell lymphomas, particularly anaplastic large cell lymphoma (ALCL).

2. Pembrolizumab (Keytruda): This is a PD-1 inhibitor that has been approved for certain types of relapsed or refractory T-cell lymphomas, including peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL).

3. Nivolumab (Opdivo): Another PD-1 inhibitor, nivolumab is used for relapsed or refractory classical Hodgkin lymphoma but has also shown efficacy in some T-cell lymphomas.

4. Duvelisib (Copiktra): This is a PI3K inhibitor that is approved for relapsed or refractory follicular lymphoma and small lymphocytic lymphoma, but it has also been studied in T-cell lymphomas.

5. Idelalisib (Zydelig): While primarily used for chronic lymphocytic leukemia (CLL) and follicular lymphoma, it has been investigated in T-cell lymphomas as well.

6. Liso-cel (Breyanzi): This is a CAR T-cell therapy that has been approved for adult patients with relapsed or refractory large B-cell lymphoma, but ongoing studies are exploring its use in T-cell lymphomas.

7. Axicabtagene ciloleucel (Yescarta): Similar to liso-cel, this CAR T-cell therapy is primarily for B-cell malignancies but is being researched for T-cell lymphomas.

8. Selinexor (Xpovio): This is an exportin 1 inhibitor that has shown activity in relapsed or refractory T-cell lymphomas.

9. Romidepsin (Istodax): This histone deacetylase inhibitor is approved for the treatment of cutaneous T-cell lymphoma and peripheral T-cell lymphoma.

10. Belinostat (Beleodaq): Another histone deacetylase inhibitor, it is approved for the treatment of relapsed or refractory PTCL.

These treatments may be used alone or in combination, depending on the specific type of T-cell lymphoma and the patient's overall health. It's essential for patients to discuss with their healthcare providers to determine the most appropriate treatment options based on their individual circumstances.

For the most current information and specific treatment recommendations, consulting the latest clinical guidelines or a healthcare professional is advisable.